The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus.
The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin).
According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.
- Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 77: S113–9. CrossRef
- Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779–802. CrossRef
- Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186–93. CrossRef
- Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–76. CrossRef
- Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493–5. CrossRef
- Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001; 33: 421–6. CrossRef
- Shibuya M. Vascular endothelial growth factor receptor-2: its unique signalling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751–6. CrossRef
- Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 1995; 376: 62–6. CrossRef
- Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70. CrossRef
- Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946–9. CrossRef
- Mura M, dos Santos CC, Stewart D, et al. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol 2004; 97: 1605–17. CrossRef
- Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527–43. CrossRef
- Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853–65.
- Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999; 13: 9–22.
- Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal out-growth through the flk-1 receptor. Eur J Neurosci 2000; 12: 4243–54. CrossRef
- Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26: 943–54. CrossRef
- Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383–94. CrossRef
- Kempen JH, O’Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552–63. CrossRef
- Klein R, Klein BE, Moss SE. The Winsconsin epidemiology study of diabetic retinopathy: a review. Diabetes Metab Rev 1989; 5: 559–70. CrossRef
- Diabetic retinopathy study group. Preliminary report on effects of photocoagulation theraphy. Am J Ophthalmol 1976; 81: 383–96.
- Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98: 766–85.
- Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoaculation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386–94. CrossRef
- Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279–99. CrossRef
- Stitt AW, Simpson DA, Boocock C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 1998; 186: 306–12. CrossRef
- Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561–8. CrossRef
- Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 43: 849–57.
- Sheetz MJ, King LK. Molecular understanding of hyperglicemia’s adverse effects for diabetic complications. JAMA 2002; 288: 2579–88. CrossRef
- Mill JW, Adamis AP, Aiello LP. Vascular endothelium growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13: 37–50. CrossRef
- Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelium growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–7. CrossRef
- Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelium growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–9. CrossRef
- Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epitheliumderived factor and vascular endothelium growth factor are related to diabetic macular edema. Ophthalmology 2006; 113: 294–301. CrossRef
- Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445–50.
- Shen J, Samul R, Silva RL, et al. Suppresion of ocular neovascularitazion with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225–34. CrossRef
- Macugen Diabetic Study group. A phase II randomised double-masked trial of pegabtanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmolgy 2005; 112: 1747–57. CrossRef
- Adamis AP, Altaweel M, Bressler NM, et al., for the Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23–8. CrossRef
- Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706–12. CrossRef
- Avery RL. Regression of retinal and iris neovascolarization after intravitreal bevacizumeb (Avastin) treatment. Retina 2006; 26: 356–7. CrossRef
- Spaide RF, Fischer YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemmorage. Retina 2006; 26: 275–8. CrossRef
- Avery RL, Pearlman J, Pieramici DJ, et al. Intraviteal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 363–72. CrossRef
- Jager RD, Aiello LP, Patel SC, et al. Risk of intravenous injection: a comprehensive review. Retina 2004; 24: 676–98. CrossRef
- Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegabtanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–16. CrossRef
- Chong NV, Adewoyin T. Intravitreal injection: balancing the risks. Eye 2007; 21: 313–6. CrossRef
- Saishin Y, Sayshin Y, Takahashi K, et al. VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of blood-retinal barrier. J Cell Physiol 2003; 195: 241–8. CrossRef
- Ryan AJ, Wedge SR. ZD647: a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92 Suppl. 1: S6–13. CrossRef
- Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389–400. CrossRef
- Hess-Stumpp H, Haberey M, Thierauch KH. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005; 6: 550–7. CrossRef
- Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005; 10: 382–91. CrossRef
- Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelium growth factorinduced retinal permeability is mediate by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997; 46: 1473–80. CrossRef
- Danis RP, Bingaman DP, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PCK β inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171–9.
- The PCK-DRS Study group. The effect of ruboxistaurin on visual loss in patients with moderately severe to severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β inhibitor Diabetic Retinopathy Study (PCK-DRS) multicenter randomised clinical trial. Diabetes 2005; 54: 2188–97. CrossRef
- Aiello LP, Clermont A, Arora V, et al. Inhibition of PCK β by oral administration of ruboxistaurine is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47: 86–92. CrossRef
- Eggers PW. Effect of transplantation on the Medicare endstage renal disease program. N Engl J Med 1988; 318: 223–6. CrossRef
- USRDS. Annual Data Report 1994. Incidence and causes of treated ESRD. Am J Kidney Dis 1994; 24: S48–56.
- Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type I (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 290–6. CrossRef
- Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42: 1457–61. CrossRef
- Khamaisi M, Schrijvers BF, De Vriese AS, et al. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003; 8: 1427–30. CrossRef
- Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 268: F240–50.
- Simon M, Rocckl W, Hornig C, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localisation and [125I]VEGF binding sites. J Am Soc Nephrol 1998; 9: 1032–44.
- Brenchley PE. VEGF/VPF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996; 9: 10–7.
- Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229–39. CrossRef
- Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579–88. CrossRef
- Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993; 36: 189–94. CrossRef
- de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993–1000.
- Sung SH, Ziyadeh FN, Wang A, et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093–104. CrossRef
- Schrijvers BF, Flyvbjerg A, Tilton RG, et al. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2006; 21: 324–9. CrossRef
- Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831–40. CrossRef
- Schrijvers BF, De Vriese AS, Tilton RG, et al. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res 2005; 37: 21–5. CrossRef
- Vinik AI, Mitchell BD, Leichter SB, et al. Epidemiology of the complications of diabetes. In: Leslie RDG, Robbins DC, editors. Diabetes: clinical science in practice. Cambridge: Cambridge University Press, 1994: 221–87.
- Skold MK. VEGF and VEGF receptor expression after experimental brain contusion in rat. J Neurotrauma 2005; 22: 353–67. CrossRef
- Mukouyama YS, Gerber HP, Ferrara N, et al. Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development 2005; 132: 941–52. CrossRef
- Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioassays 2004; 26: 943–54. CrossRef
- Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083–92. CrossRef
- Murakami T, Arai M, Sunada Y, et al. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006; 8: 773–81. CrossRef
- Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000; 6: 405–13. CrossRef
- Chattopadhyay M, Krisky D, Wolfe D, et al. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 2005; 12: 1377–84. CrossRef
- Price SA, Dent C, Duran-Jimenez B, et al. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 2006; 55: 1847–54. CrossRef
- The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications
American Journal of Cardiovascular Drugs
Volume 7, Issue 6 , pp 393-398
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. Department of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute, Milan, Italy
- 2. Renal Pathophysiology Unit, San Raffaele Scientific Institute, Milan, Italy
- 3. Division of Medicine, San Raffaele Scientific Institute, Via Olgettina, Milan, 60 I — 20132, Italy